Patients must have MRD-level disease only and otherwise meet criteria for complete response (CR) or complete remission with incomplete hematologic recovery (CRi) per the 2017 European LeukemiaNet response criteria ( Patients must have received at least 1-2 cycles of standard induction chemotherapy prior to enrollment on the study. However, adult patients (>= 18 years of age) are eligible for participation at any time point in treatment (after induction, during or after consolidation, pre-transplant, or post-transplant). Pediatric patients (2-18 years of age) must have MRD positivity during/after consolidation or post-transplant.
Eastern Cooperative Oncology Group (ECOG) performance status == 40 (for children).
Patient's AML blasts must have CD33 expression.
For adults (>= 18 years of age): Serum creatinine = For adults (>= 18 years of age): Total bilirubin = For adults (>= 18 years of age): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) For children ( For children ( For children ( Ability of patient or representative to provide written informed consent.
Females of childbearing potential must have a negative pregnancy test prior to receiving GO.
Other eligibility criteria may apply.
Subjects may not be receiving other investigational agents.
Uncontrolled or concurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Other exclusion criteria may apply.